[1]
Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. The Lancet. Oncology. 2010 Oct:11(10):983-91. doi: 10.1016/S1470-2045(10)70023-1. Epub 2010 May 25
[PubMed PMID: 20537949]
[2]
Young RJ, Woll PJ. Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update. Memo. 2017:10(4):190-193. doi: 10.1007/s12254-017-0365-x. Epub 2017 Nov 7
[PubMed PMID: 29250195]
[4]
Fujisawa Y, Yoshino K, Fujimura T, Nakamura Y, Okiyama N, Ishitsuka Y, Watanabe R, Fujimoto M. Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor. Frontiers in oncology. 2018:8():46. doi: 10.3389/fonc.2018.00046. Epub 2018 Mar 2
[PubMed PMID: 29552543]
[5]
Yadav U, Mangla A. Primary pericardial angiosarcoma: case report and review of treatment options. Ecancermedicalscience. 2020:14():1056. doi: 10.3332/ecancer.2020.1056. Epub 2020 Jun 15
[PubMed PMID: 32582371]
Level 3 (low-level) evidence
[6]
Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchère D, Sastre X, Vilain MO, Bonichon F, N'Guyen Bui B. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001 May 15:91(10):1914-26
[PubMed PMID: 11346874]
[7]
Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S. : an analysis of 12,114 cases. Cancer. 2008 Aug 1:113(3):616-27. doi: 10.1002/cncr.23571. Epub
[PubMed PMID: 18618615]
Level 3 (low-level) evidence
[8]
Ohsawa M, Naka N, Tomita Y, Kawamori D, Kanno H, Aozasa K. Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases. Cancer. 1995 Jun 15:75(12):2867-74
[PubMed PMID: 7773935]
Level 3 (low-level) evidence
[9]
Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS, Rees R, Sondak VK. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003 Oct 15:98(8):1716-26
[PubMed PMID: 14534889]
[10]
Hillenbrand T, Menge F, Hohenberger P, Kasper B. Primary and secondary angiosarcomas: a comparative single-center analysis. Clinical sarcoma research. 2015:5():14. doi: 10.1186/s13569-015-0028-9. Epub 2015 May 23
[PubMed PMID: 26413264]
Level 2 (mid-level) evidence
[11]
Tokmak E, Ozkan E, Yağcı S, Kır KM. F18-FDG PET/CT Scanning in Angiosarcoma: Report of Two Cases. Molecular imaging and radionuclide therapy. 2011 Aug:20(2):63-6. doi: 10.4274/MIRT.020397. Epub 2011 Aug 1
[PubMed PMID: 23486298]
Level 3 (low-level) evidence
[12]
Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C, Bonvalot S, Ranchère D, Pouillart P, Coindre JM, Blay JY. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Dec:18(12):2030-6
[PubMed PMID: 17974557]
Level 2 (mid-level) evidence
[13]
Mangla A, Gupta A, Mansur DB, Abboud S, Rothermel LD, Oliveira GH. Right atrial cardiac angiosarcoma treated with concurrent proton beam therapy and paclitaxel: A novel approach to a rare disease. Thoracic cancer. 2021 Apr:12(7):1131-1133. doi: 10.1111/1759-7714.13895. Epub 2021 Feb 19
[PubMed PMID: 33605065]
[14]
Mocellin S, Rossi CR, Brandes A, Nitti D. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer treatment reviews. 2006 Feb:32(1):9-27
[PubMed PMID: 16338075]
[15]
Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005 Jul 15:104(2):361-6
[PubMed PMID: 15948172]
[16]
Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 10:26(32):5269-74. doi: 10.1200/JCO.2008.17.3146. Epub 2008 Sep 22
[PubMed PMID: 18809609]
[17]
Apice G, Pizzolorusso A, Di Maio M, Grignani G, Gebbia V, Buonadonna A, De Chiara A, Fazioli F, De Palma G, Galizia D, Arcara C, Mozzillo N, Perrone F. Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma. Sarcoma. 2016:2016():6862090. doi: 10.1155/2016/6862090. Epub 2016 Feb 25
[PubMed PMID: 27019606]
[18]
Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, Castle JC, Buell JS, Trent JC, Wilky BA. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. Journal for immunotherapy of cancer. 2019 Aug 8:7(1):213. doi: 10.1186/s40425-019-0689-7. Epub 2019 Aug 8
[PubMed PMID: 31395100]
Level 2 (mid-level) evidence
[19]
Abraham JA, Hornicek FJ, Kaufman AM, Harmon DC, Springfield DS, Raskin KA, Mankin HJ, Kirsch DG, Rosenberg AE, Nielsen GP, Desphpande V, Suit HD, DeLaney TF, Yoon SS. Treatment and outcome of 82 patients with angiosarcoma. Annals of surgical oncology. 2007 Jun:14(6):1953-67
[PubMed PMID: 17356953]
[20]
Eitan T, Damico NJ, Pidikiti R, Kharouta MZ, Dobbins D, Jesseph FB, Smith M, Mangla A, Teknos TN, Mansur DB, Machtay M, Yao M, Bhatt AD. Reirradiation for Recurrent Scalp Angiosarcoma: Dosimetric Advantage of PBT over VMAT and EBT. International journal of particle therapy. 2020 Winter:6(3):13-18. doi: 10.14338/IJPT-19-00074. Epub 2019 Dec 16
[PubMed PMID: 32582810]